At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
In Brief
A Phase 4 clinical trial evaluating Ondansetron and Placebo for Obsessive-Compulsive Disorder and 2 related conditions. Completed, enrolled 110 participants across 2 sites.
Detailed Summary
This project investigates the use of 4 weeks of 24 mg/day ondansetron as compared to placebo on symptoms and brain functioning in patients with obsessive-compulsive disorder (OCD) and tic disorders (TD). Patients will be randomized to receive ondansetron or placebo for 4 weeks, with MRI scans and symptom assessments occurring at baseline (before any drug) and at the end of the 4 weeks. Patients will also be asked to come into the lab approximately 2 weeks into the trial for symptom assessments. The investigators hypothesize that after 4 weeks there will be greater reduction from baseline in sensory symptoms and the activation of the insula and sensorimotor cortex compared for ondansetron as compared to placebo.
Study Details
Timeline
Interventions
5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
placebo equivalent